• Je něco špatně v tomto záznamu ?

Chelation of Mitochondrial Iron as an Antiparasitic Strategy

D. Arbon, J. Mach, A. Čadková, A. Sipkova, J. Stursa, K. Klanicová, M. Machado, M. Ganter, V. Levytska, D. Sojka, J. Truksa, L. Werner, R. Sutak

. 2024 ; 10 (2) : 676-687. [pub] 20240130

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007171

Grantová podpora
U10 CA021115 NCI NIH HHS - United States

Iron, as an essential micronutrient, plays a crucial role in host-pathogen interactions. In order to limit the growth of the pathogen, a common strategy of innate immunity includes withdrawing available iron to interfere with the cellular processes of the microorganism. Against that, unicellular parasites have developed powerful strategies to scavenge iron, despite the effort of the host. Iron-sequestering compounds, such as the approved and potent chelator deferoxamine (DFO), are considered a viable option for therapeutic intervention. Since iron is heavily utilized in the mitochondrion, targeting iron chelators in this organelle could constitute an effective therapeutic strategy. This work presents mitochondrially targeted DFO, mitoDFO, as a candidate against a range of unicellular parasites with promising in vitro efficiency. Intracellular Leishmania infection can be cleared by this compound, and experimentation with Trypanosoma brucei 427 elucidates its possible mode of action. The compound not only affects iron homeostasis but also alters the physiochemical properties of the inner mitochondrial membrane, resulting in a loss of function. Furthermore, investigating the virulence factors of pathogenic yeasts confirms that mitoDFO is a viable candidate for therapeutic intervention against a wide spectrum of microbe-associated diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007171
003      
CZ-PrNML
005      
20240423155752.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acsinfecdis.3c00529 $2 doi
035    __
$a (PubMed)38287902
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Arbon, Dominik $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic $1 https://orcid.org/0000000224595446
245    10
$a Chelation of Mitochondrial Iron as an Antiparasitic Strategy / $c D. Arbon, J. Mach, A. Čadková, A. Sipkova, J. Stursa, K. Klanicová, M. Machado, M. Ganter, V. Levytska, D. Sojka, J. Truksa, L. Werner, R. Sutak
520    9_
$a Iron, as an essential micronutrient, plays a crucial role in host-pathogen interactions. In order to limit the growth of the pathogen, a common strategy of innate immunity includes withdrawing available iron to interfere with the cellular processes of the microorganism. Against that, unicellular parasites have developed powerful strategies to scavenge iron, despite the effort of the host. Iron-sequestering compounds, such as the approved and potent chelator deferoxamine (DFO), are considered a viable option for therapeutic intervention. Since iron is heavily utilized in the mitochondrion, targeting iron chelators in this organelle could constitute an effective therapeutic strategy. This work presents mitochondrially targeted DFO, mitoDFO, as a candidate against a range of unicellular parasites with promising in vitro efficiency. Intracellular Leishmania infection can be cleared by this compound, and experimentation with Trypanosoma brucei 427 elucidates its possible mode of action. The compound not only affects iron homeostasis but also alters the physiochemical properties of the inner mitochondrial membrane, resulting in a loss of function. Furthermore, investigating the virulence factors of pathogenic yeasts confirms that mitoDFO is a viable candidate for therapeutic intervention against a wide spectrum of microbe-associated diseases.
650    12
$a železo $7 D007501
650    _2
$a deferoxamin $x chemie $7 D003676
650    _2
$a antiparazitární látky $x farmakologie $7 D000977
650    _2
$a chelátory železa $x farmakologie $x terapeutické užití $7 D007502
650    _2
$a mitochondrie $7 D008928
650    12
$a antiinfekční látky $7 D000890
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mach, Jan $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic
700    1_
$a Čadková, Aneta $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic
700    1_
$a Sipkova, Anna $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic
700    1_
$a Stursa, Jan $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic $u Laboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic
700    1_
$a Klanicová, Kristýna $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic $u Department of Organic Chemistry, Faculty of Science, Charles University, Prague 128 00, Czech Republic
700    1_
$a Machado, Marta $u Graduate Program in Areas of Basic and Applied Biology, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto 4050-313, Portugal $u Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany
700    1_
$a Ganter, Markus $u Centre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg 69120, Germany
700    1_
$a Levytska, Viktoriya $u Institute of Parasitology, Biology Centre, Academy of Sciences of the Czech Republic, Branišovská 1160/31, České Budějovice 37005, Czech Republic
700    1_
$a Sojka, Daniel $u Institute of Parasitology, Biology Centre, Academy of Sciences of the Czech Republic, Branišovská 1160/31, České Budějovice 37005, Czech Republic
700    1_
$a Truksa, Jaroslav $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic
700    1_
$a Werner, Lukáš $u Institute of Biotechnology, Czech Academy of Sciences, BIOCEV, Vestec 25250, Czech Republic $u Laboratory of Clinical Pathophysiology, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic
700    1_
$a Sutak, Robert $u Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec 25250, Czech Republic $1 https://orcid.org/0000000155881683 $7 xx0254258
773    0_
$w MED00205751 $t ACS infectious diseases $x 2373-8227 $g Roč. 10, č. 2 (2024), s. 676-687
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38287902 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155749 $b ABA008
999    __
$a ok $b bmc $g 2081264 $s 1216938
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 2 $d 676-687 $e 20240130 $i 2373-8227 $m ACS infectious diseases $n ACS infect. dis. $x MED00205751
GRA    __
$a U10 CA021115 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace